Developing Targeted Therapeutics: What You Need to Know

Sign Up and Keep Learning

There is always more to learn. Introduce yourself for full access to all LI-COR webinars.

Want access to all LI-COR webinars? First, you will need to accept cookies.
Open Cookie Preferences

We are unable to display the form due to your browser’s privacy settings. Please fill out the form here. If you need further assistance, please contact formsupport@licor.com

When you complete this form, your information is collected by LICORbio (United States) and shared with LI-COR and its subsidiaries, LI-COR INC, LI-COR GmbH (Germany) and LI-COR Ltd (United Kingdom). LI-COR and its subsidiaries work closely together to provide scientific expertise and prompt responses to customers globally. Depending on your location, your information may also be shared with a distribution partner. For more details, view our Privacy Policy (www.licor.com/privacy) or contact privacy@licor.com.

 

Developing Targeted Therapeutics: What You Need to Know

Targeted therapeutics development can be a challenging but necessary aspect of your research. To help alleviate its complexity, we’ve compiled several important ways you can reach your scientific goals quickly, accurately, and efficiently. You can therefore minimize your use of valuable resources and spend more time pursuing and prioritizing your work. 

In this webinar, learn about the different ways that therapeutic assays are being used in current research initiatives around the world. Gain a better understanding of how preclinical research and clinical trials can guide you through the process of targeted therapeutics development. Then see how you can maximize your own research with LI-COR, whose innovative technology and team of experts can help you continue advancing science every step of the way.


About the Speaker:

Dr. Gretchen Hubbard is a Senior Solutions and Support Scientist and Cell-Based Assays Leader at LI-COR Biosciences. She finished her doctoral degree from the University of Maryland Baltimore County where she studied the combinatorial effects of oncogenic expression and tumor suppressor loss in mouse prostate cancer models. She then completed a postdoctoral fellowship at Johns Hopkins University School Medicine in genitourinary pathology, where she identified novel genomic changes associated with prostate cancer progression and examined the role inflammation plays in prostate cancer initiation.